![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-desktop-headergif-63893.gif)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-mobile-headergif-78265.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
UTD1 (utidelone) is an investigational tubulin inhibitor, given intravenously in combination with capecitabine for its potential efficacy in patients with HER2-negative breast cancer brain metastases.
Lead Product(s): Utidelone,Capecitabine
Therapeutic Area: Oncology Product Name: UTD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2024
Details:
UTD1 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of breast cancer brain metastasis.
Lead Product(s): Utidelone,Bevacizumab,Etoposide
Therapeutic Area: Oncology Product Name: UTD1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2024
Details:
UTD2 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of gastric cancer.
Lead Product(s): Utidelone
Therapeutic Area: Oncology Product Name: UTD2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
UTD2 (utidelone capsule) is the first oral epothilone microtubule inhibitor, which is investigated for the treatment of advanced solid tumor patients in the US.
Lead Product(s): Utidelone
Therapeutic Area: Oncology Product Name: UTD1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
UTD2 (utidelone capsule) is the first oral epothilone microtubule inhibitor and which is investigated for the treatment of advanced solid tumor patients in the US.
Lead Product(s): Utidelone
Therapeutic Area: Oncology Product Name: UTD2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023